Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety

Adverum Biotechnologies Inc ADVM announced new long-term data from the OPTIC trial of ADVM-022 gene therapy for neovascular or wet age-related macular degeneration (wet AMD).
Data were shared at the Retina Society's Annual Scientific Meeting.
The 2 x 10^11 vg/eye dose (n=15), planned to be evaluated in a future Phase 2 trial, showed an over 80% reduction in annualized anti-VEGF injection frequency in patients who previously required frequent injections.
Over 50% of patients after a median follow-up of 1.7 years remained entirely free of any supplemental anti-VEGF injection.
Retinal anatomy (mean Central subfield thickness versus baseline) to improved and vision (mean BCVA versus baseline) was maintained over time.
All ADVM-022-related ocular adverse events were mild (81%) to moderate (19%) across all wet AMD patients.
At the 2 x 10^11 vg/eye dose, ocular inflammation was minimal and responsive to steroid eye drops.
The Company plans to present INFINITY trial data in diabetic macular edema at the American Society of Retina Specialists Annual Scientific Meeting.
Related: Adverum Stock Falls As It Stops Testing Ocular Gene Therapy Candidate In Diabetic Macular Edema Patients.
Price Action: ADVM stock is up 6.88% at $2.33 during the premarket session on the last check Monday.